Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.57 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.48 |
| ▸ | CKS1B | P61024 | 1/20 | 0.47 |
| ▸ | SKP1 | P63208 | 1/20 | 0.47 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.47 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107842 | 0.88 | GPR119 (0.64) | GPR119PTPN11ACHECKS1BSKP1 | |
| SCHEMBL3605523 | 0.86 | GPR119 (0.59) | GPR119PTPN11MAPTACHECKS1B | |
| SCHEMBL16652717 | 0.86 | GPR119 (0.59) | GPR119PTPN11MAPTACHECKS1B | |
| SCHEMBL12480371 | 0.86 | GPR119 (0.56) | GPR119PTPN11MAPTACHECKS1B | |
| SCHEMBL23560892 | 0.86 | GPR119 (0.56) | GPR119PTPN11MAPTACHECKS1B | |
| SCHEMBL15007622 | 0.84 | GPR119 (0.65) | GPR119PTPN11MAPTACHECKS1B | |
| SCHEMBL16651945 | 0.84 | GPR119 (0.54) | GPR119PTPN11MAPTACHECKS1B | |
| SCHEMBL30313118 | 0.84 | NPC1 (0.62) | GPR119CKS1BSKP1SKP2OGA | |
| SCHEMBL19283866 | 0.84 | NPC1 (0.62) | GPR119CKS1BSKP1SKP2OGA | |
| SCHEMBL1447940 | 0.83 | GPR119 (0.65) | GPR119PTPN11MAPTACHECKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-05-15 | — | — | US | disclosed |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2025-04-10 | — | — | US | disclosed |
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ASCENEURON SA (CH) | 2024-12-03 | — | — | US | disclosed |
| EP-4444717-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | University of Florida Research Foundation, Incorporated (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-110770226-B | Sulfoximine glycosidase inhibitors | 阿森纽荣股份公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023107606-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-06-15 | — | — | WO | disclosed |
| CN-116157396-A | Pyridazinone derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-06-09 | — | — | US | disclosed |
| WO-2022111700-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF IN MEDICINE | 成都百裕制药股份有限公司 | 2022-06-02 | — | — | WO | disclosed |
| WO-2017046036-A1 | COMPOUNDS FOR THE MODULATION OF RIP2 KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536168-B2 | Benzyl and pyridinyl derivatives as modulators of the hedgehog signaling pathway | NOVARTIS AG (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| US-20100069368-A1 | Organic Compounds and Their Uses | NOVARTIS AG (CH) | 2010-03-18 | — | — | US | disclosed |
| EP-2137162-A1 | ORGANIC COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008110611-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12157734-B2 | Sulfoximine glycosidase inhibitors | ENGASE, BACE1, GAA | GPR119 975/4885PTPN11 1971/4885MAPT 42/4885 |
| US-20220177470-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | GPR119 975/4885PTPN11 1971/4885MAPT 42/4885 |
| US-20250154141-A1 | BCL-XL/BCL-2 DUAL DEGRADERS FOR TREATMENT OF CANCERS | BCL2, BCL2L2, BCL2L1 | GPR119 2536/4885PTPN11 2931/4885MAPT 4377/4885 |
| US-20250115604-A1 | SULFOXIMINE GLYCOSIDASE INHIBITORS | ENGASE, BACE1, GAA | GPR119 1081/4885PTPN11 1859/4885MAPT 38/4885 |
| US-20100069368-A1 | Organic Compounds and Their Uses | SHH, GLI1, VHL | GPR119 4541/4885PTPN11 1580/4885MAPT 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.